The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with ...

AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated ...

EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...

CALY-002 is under development for the treatment of eosinophilic esophagitis, celiac disease and unspecified dermatological disorders. It is a fully-humanized monoclonal antibody also administered ...

That changed on Tuesday however, as the FDA signed off on Fasenra for patients with eosinophilic granulomatosis with ...

The parasite that causes the disease, Baylisascaris procyonis, lives in the intestines of raccoons. While it doesn't make ...

Endoscopic biopsies are essential in cell-mediated disorders and allergic eosinophilic gastropathies. Treatment includes avoidance of the offending food by a restriction diet in children and the ...

First described nearly 20 years ago, eosinophilic esophagitis (EoE ... both a rising incidence and increased recognition of this disorder. Treatment options available for patients with EoE ...

CALY-002 is under development for the treatment of eosinophilic esophagitis, celiac disease and unspecified dermatological disorders. It is a fully-humanized monoclonal antibody also administered ...

Post-Covid, there has been considerable advancement in integrating video conferencing into meeting spaces. However, users continue to seek more engaging and collaborative experiences, taking into ...

The gastrointestinal microbiome remains an explosively increasing topic of study, assessing the potentially pivotal roles of the microbiome in maintaining health or causality in disease pathogenesis.